"In addition to the cash available, the total estimated cash outflows next quarter is expected to be well supported by cash receipt from sales revenue and the availability of R&D Tax Advance secured by the provision of R&D Tax Incentive 2017/2018."
Seems like there might not be a cap raise.... but who knows.
Also note Product Manufacturing costs will double next quarter, so this should (hopefully) coincide with an increase in sales revenue - likely from the Labcon deal.
Add to My Watchlist
What is My Watchlist?
